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Purpose: Photothermal therapy is an emerging cancer treatment paradigm which involves 
highly localized heating and killing of tumor cells, due to the presence of nanomaterials that 
can strongly absorb near-infrared (NIR) light. In addition to having deep penetration depths 
in tissue, NIR light is innocuous to normal cells. Little is known currently about the fate of 
nanomaterials post photothermal ablation and the implications thereof. The purpose of this 
investigation was to define the intratumoral fate of nanoparticles (NPs) after photothermal 
therapy in vivo and characterize the use of novel multidye theranostic NPs (MDT-NPs) for 
fractionated photothermal antitumor therapy.
Methods: The photothermal and fluorescent properties of MDT-NPs were first characterized. 
To investigate the fate of nanomaterials following photothermal ablation in vivo, novel MDT-
NPs and a murine mammary tumor model were used. Intratumoral injection of MDT-NPs and 
real-time fluorescence imaging before and after fractionated photothermal therapy was performed 
to study the intratumoral fate of MDT-NPs. Gross tumor and histological changes were made 
comparing MDT-NP treated and control tumor-bearing mice.
Results: The dual dye-loaded mesoporous NPs (ie, MDT-NPs; circa 100 nm) retained both 
their NIR absorbing and NIR fluorescent capabilities after photoactivation. In vivo MDT-NPs 
remained localized in the intratumoral position after photothermal ablation. With   fractionated 
photothermal therapy, there was significant treatment effect observed macroscopically (P = 0.026) 
in experimental tumor-bearing mice compared to control treated tumor-bearing mice.
Conclusion: Fractionated photothermal therapy for cancer represents a new therapeutic   paradigm 
enabled by the application of novel functional nanomaterials. MDT-NPs may advance clinical 
treatment of cancer by enabling fractionated real-time image guided photothermal therapy.
Keywords: fluorescence, mesoporous silica, biodistribution, photothermal ablation, live animal 
imaging, near-infrared nanoparticle, breast cancer
Introduction
Photothermal ablation is an exciting noninvasive cancer paradigm,1–5 which is just 
  beginning to enter the clinical arena for human cancer therapy.6 Numerous   nanomaterials 
including nanoshells,1,2 polyhydroxy fullerenes,5 gold speckled silica nanoparticles 
(NPs),7 gold NPs,8 gold nanorods,3 nanotubes,9,10 nanocages,11 and quantum dots12 have 
been investigated as anticancer photothermal agents.   Numerous studies have demon-
strated the efficacy of these nanomaterials for tumor ablation in vitro.2,7,8,13 Several 
studies have focused on the effect of photothermal therapy using these   nanomaterials 
using in vivo models.1,10,13 These in vivo studies have demonstrated that a single pho-
tothermal treatment results in partial but incomplete tumor   destruction based on long 
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term follow-up of tumor growth.10,13 Approaches and strate-
gies to improve the efficacy of the photothermal antitumor 
strategy are needed.
Little is known about the biodistribution of photother-
mally active NPs following photothermal tumor ablation. 
Understanding the intratumoral fate of nanomaterials after 
photothermal therapy is essential for furthering the clinical 
application of nanoparticle-mediated photothermal therapy. 
To investigate this issue in vivo requires the development 
and application of nanomaterials that are not only robust 
photothermal reagents, but also stable bioimaging contrast 
agents. Magnetic resonance imaging,1 optical coherence 
tomography,13 and photoacoustic imaging14 have been used to 
guide photothermal treatments in vivo. Near-infrared (NIR) 
fluorescence imaging has not been utilized commonly to 
track photothermal nanomaterials in vivo due to difficulties in 
combining plasmonic materials with a fluorescent component 
into single, biocompatible nanoconstructs.15
In this report, novel multidye theranostic NPs (MDT-NPs) 
were employed to address the fate of nanomaterials following 
photothermal ablation. These recently developed NPs are 
biocompatible, have strong and stable NIR fluorescence, 
and robust NIR photothermal properties.16 The unique multi-
functionality and stability of these novel nanomaterials favor 
their application to answer these questions regarding the fate 
of nanomaterials of photothermal therapies. In this report, 
the ability of MDT-NPs to mediate enhanced photothermal 
tumor destruction when utilized for multiple fractionated 
ablations is demonstrated. The findings suggest fractionated 
photothermal therapy as a new paradigm for noninvasive 
image-guided cancer therapy.
Materials and methods
NIR fluorescent (NIRF) mesoporous silica NPs16 were syn-
thesized by incorporating a modified, silane-conjugated hep-
tamethine cyanine dye (IR780; Sigma-Aldrich Corporation, 
St Louis, MO) during the synthesis of mesoporous silica NPs, 
as described elsewhere.16 Briefly, 0.5 g of cetyltrimethylam-
monium bromide (C16TAB; Sigma-Aldrich) and 1.75 mL 
of 2 M sodium hydroxide (Fisher Scientific Co, Pittsburgh, 
PA) were added to 240 mL of Nanopure water (Fisher Sci-
entific) and heated to 80°C. Once thermal equilibrium was 
reached, 2.5 mL of tetraethyl orthosilicate (Fisher Scientific) 
was added dropwise to this solution. After 2–3 minutes, the 
transparent solution turned milky due to the nucleation of 
silica NPs. At this time, 800 µL of silane conjugated dye was 
added. The particle suspension was allowed to stir for 3 hours 
at constant temperature of 80°C.
For the removal of surfactant, particles were dispersed 
in 3 wt% methanolic solution of calcium chloride (Fisher 
Scientific) and the suspension was refluxed for 4 hours at 
60°C. For 1 g particles, 100 mL of calcium chloride-methanol 
solution was used. These particles were centrifuged (7000 × g, 
20 min; Beckman Model J2-21, APE-Bridgepath Scientific, 
Frederick, MD) and resuspended in the calcium chloride-
methanol solution with the aid of sonication (Crest Tru-Sweep 
Model 575D; Crest Ultrasonics, Trenton, NJ). The refluxing/
centrifugation/resuspension steps were repeated three times 
in order to completely remove the surfactant from the pores. 
Finally, these particles were suspended in Nanopure water by 
centrifugation and resuspension using sonication. To confirm 
the complete removal of surfactant, the NPs were incubated 
with cells and a lactate dehydrogenase assay (Roche Diagnos-
tics, Indianapolis, IN) was performed; the assay demonstrated 
no deleterious effects on cells.
For the synthesis of MDT-NPs, NIRF mesoporous particles 
were dispersed in chloroform (Fisher Scientific) to encapsulate 
the photothermal dye inside the pores. In a typical synthesis, 
NIRF mesoporous silica NPs (10 mg) were dispersed in 8 mL 
chloroform. Then, 2 mg of silicon 2,3-naphthalocyanine dihy-
droxide (Sigma-Aldrich) in chloroform (concentration 1 mg/mL) 
was added to the nanoparticle dispersion. The dispersion was 
stirred overnight to allow for the maximum loading of the dyes 
into the NP pores. Particles were washed by centrifugation and 
were redispersed in water for further experiments. Measuring 
the absorbance of the supernatant allowed an estimate of the 
amount of dye incorporated inside the pores of the NPs (11.1%). 
Nanoparticles were characterized for absorbance, emission, and 
heating using techniques detailed elsewhere.16
The 4T1 murine mammary tumor cell line (Tufts 
University, Medford, MA) was orthotopically implanted 
(1 × 106 cells) into female 6-week-old BALB/c mice (Charles 
River Laboratories, Wilmington, MA). On postimplantation 
day eight, 27 mice were equally and randomly distributed to 
nine groups (three mice per group): MDT-NP/no ablation, 
MDT-NP/one ablation, MDT-NP/two ablations, MDT-NP/
three ablations, MDT-NP/four ablations, control/one ablation, 
control/two ablations, control/three ablations, control/four 
ablations. Only one ablation was performed per day per mouse. 
At the start of the experiment, mice were initially imaged via 
fluorescence (710 nm excitation/820 nm emission) with the 
IVIS® Spectrum (Caliper Life Sciences, Hopkinton, MA). For 
in vivo imaging experiments, 820 nm wavelength was chosen 
as it provides the greatest signal to noise ratio.
This was followed by administration of MDT-NPs via 
intratumoral injection (15 mg/mL, 20 µL) or 0.9% sterile 
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saline solution (20 µL; Fisher Scientific) for control mice. 
Fluorescence imaging was obtained on all mice after intratu-
moral injection. Mice then underwent photothermal ablation 
(continuous wave laser, 785 nm, 625 mW/cm2, 5 minute dura-
tion, 1.5 cm source-tumor distance). Fluorescence imaging 
was also obtained after each photothermal ablation.
For imaging and ablation experiments, mice were 
anesthetized using 2%–3% isoflurane (Baxter Healthcare 
Corporation, Deerfield, IL). On day nine, whole animal digital 
photographs (D90; Nikon, Melville, NY) were obtained before 
mice were   euthanized. Severity of treatment effect was based 
on gross tumor inspection (experiment day nine) and scored in 
a blinded fashion using a scale of zero (no treatment) to four 
(maximal treatment effect). After euthanization, tumors were 
harvested and in situ organ fluorescence images were obtained. 
Tumors were preserved in 10% neutral buffered formalin 
(Fisher Scientific) for histological analysis. Histological 
tumor analysis was performed in a blinded fashion by a board 
certified pathologist (JAK). Region of interest quantification 
of fluorescent signal was performed at all imaging points with 
Living Image® 3.2 or 4.0 software (Caliper Life Sciences).
Statistical analysis was performed on the severity of tumor 
necrosis using the Kruskal–Wallis test (SAS   Institute, Inc, 
Cary, NC). P , 0.05 was considered statistically   significant. 
All experiments were performed under protocols approved 
by the University of Florida Institutional Animal Care and 
Use Committee.
Results
MDT-NPs were synthesized using a two-step approach.16 
First, NIRF mesoporous silica NPs were synthesized by 
incorporating a modified, silane-conjugated heptamethine 
cyanine dye (IR780) during the surfactant-templated syn-
thesis of mesoporous silica NPs. Second, for the synthesis 
of MDT-NPs, these NIRF mesoporous NPs were dispersed 
in chloroform to encapsulate the NIR photothermal silicon 
2,3-naphthalocyanine dihydroxide dye inside the pores of 
the silica matrix. The final nanoconstructs were washed and 
dispersed in water for the subsequent sequential photothermal 
ablation experiments and visualization.
The photophysical properties (absorbance and fluorescence) 
of NIRF NPs are presented in Figure 1A. The broad excitation 
spectra and large Stoke’s shift of the particles enabled use of a 
broad range of excitation wavelengths and decreased the extent 
of self-quenching, respectively. Having a porous interior struc-
ture, these NPs were circa 100 nm, as measured by transmission 
electron microscope (JEOL 2010F, Tokyo, Japan) (Figure 1D). 
Upon loading of a silicon 2,3-naphthalocyanine dihydroxide 
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Figure  1  (A)  Normalized  absorbance  and  fluorescence  of  multidye  theranostic 
nanoparticles.  (B) Normalized ultraviolet-visible absorbance spectra of nanoparticles 
before (i) and after (ii) loading of silicon 2,3-naphthalocyanine dihydroxide dye. (C) Thermal 
properties of multidye theranostic nanoparticles. The 785-nm laser irradiated the same 
aqueous dispersion of multidye theranostic nanoparticles (1 mg/mL) on three separate 
days demonstrating that the multidye theranostic nanoparticles retain their photothermal 
properties after activation with near-infrared light. (D) Transmission electron micrograph 
of multidye theranostic nanoparticles. The porous structure of particles is evident in the 
image.
Note: Scale bar represents 100 nm.
Abbreviation: MDT-NP, multidye theranostic nanoparticle. 
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dye into the pores of NIRF NPs, their absorption cross-section 
in the NIR region increased (Figure 1B); the broad extinction 
spectra of these MDT-NPs displayed their ability to absorb light 
over the entire NIR region. The ability of MDT-NPs to absorb 
NIR light and generate heat was tested by measuring the tem-
perature increase of an aqueous dispersion of MDT-NPs upon 
illumination with a low power laser source (785 nm, 625 mW/
cm2). The temperature of a solution of MDT-NPs (1 mg/mL) 
increased by approximately 15°C after 5 minutes of continu-
ous irradiation. The repeated heating over a period of 3 days 
resulted in only partial loss (∼4% decrease in temperature on 
day three relative to day one) of their heat generating capacity 
(Figure 1C).
Next, a murine orthotopic model of breast cancer was 
used to study the fate of MDT-NPs following photothermal 
ablation in vivo. After intratumoral injection of MDT-NPs, 
mammary tumors in mice were exposed to NIR laser light 
once daily for 1, 2, 3, or 4 days. After each NIR irradiation 
event, the fluorescence signal was plotted by normalizing 
each signal to the intensity of the original injected MDT-NPs 
(day one before ablation, Figure 2). Following a single injec-
tion of MDT-NPs, all experimental groups (both with and 
without laser irradiation) showed a consistent intratumoral 
fluorescence pattern for 9 days. A decrease in fluorescence 
signal occurred over time for each experimental group. Impor-
tantly, MDT-NPs could easily been seen in the intratumoral 
position for the entire 9-day observation period in all groups. 
Figure 3 is a fluorescence imaging sequence over a time 
course of 9 days of a representative mouse from the MDT-
NP/four ablations group. After 9 days, MDT-NPs retained 
high fluorescence imaging capacity and remained within the 
tumor. In order to determine if MDT-NPs were accumulating 
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Figure 2 Nine-day time course of normalized fluorescent signal before and after 
photothermal  ablation  of  control  (no  ablation)  and  sequentially  ablated  groups. 
This demonstrates persistence of the multidye theranostic nanoparticles within the 
tumor over 9 days.
Note:  Error  bars  shown  represent  the  standard  error  of  the  mean  for  each 
measurement.
Abbreviation: MDT-NPs, multidye theranostic nanoparticles.
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Figure 3 Fluorescence image (710 nm excitation/820 nm emission) of a mouse 
(A)  before  direct  intratumoral  multidye  theranostic  nanoparticle  injection,  (B) 
after injection, and (C) after photothermal ablation on day one. This representative 
mouse underwent daily photothermal ablation (multidye theranostic nanoparticle/
four total ablations) with subsequent fluorescent imaging on (D) day two, (E) day 
three, and (F) day four. The mouse was further imaged on (G) day five, (H) day 
seven, and (I) day nine to determine fate of multidye theranostic nanoparticles 
after photothermal ablation. Region of interest is quantified in photons/second. 
Image acquisition settings: excitation filter = 710 nm, emission filter = 820 nm, 
binning = small, field of view = 13.2 cm, f-stop = 2, exposure = (A) 1, (B) 3, (C) 3, 
(D) 3, (E) 3, (F) 4, (G) 5, (H) 6, and (I) 6 seconds. Fluorescent in-situ image (710 nm 
excitation/820 nm emission) of a representative euthanized mouse (J) multidye 
theranostic nanoparticle/no ablation, (K) multidye theranostic nanoparticle/four 
ablations, and (L) control/four ablations.
Notes: There is no accumulation of multidye theranostic nanoparticles observed 
in other organs including the liver and spleen. Image acquisition settings: excitation 
filter = 710 nm, emission filter = 820 nm, binning = medium, field of view = 13.2 cm, 
f-stop = 2, exposure = 1 second.
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Figure 4 Graph of tumor treatment score in experimental and control mice. Tumor treatment effect was scored in a blinded fashion using a scale of zero (no treatment 
effect) to four (maximal treatment effect) as determined on experiment day nine.
Notes: Median values are shown with range of values shown in parentheses above the bars. There was a statistical difference in treatment effect score in the treatment 
groups (P = 0.026).
Abbreviation: MDT-NPs, multidye theranostic nanoparticles.
in reticuloendothelial organs (liver and spleen) following 
photothermal ablation therapy, whole animal organ in situ 
fluorescence imaging was performed following primary tumor 
removal on day nine. No MDT-NPs were detected beyond the 
intratumoral injection site in these mice (Figure 3).
The persistence of MDT-NPs within the tumor for 
9 days following administration suggests the possibility 
for fractionated image-guided photothermal therapy after a 
single administration of MDT-NPs to a tumor. Increasing the 
number of ablation fractions corresponded to a significant 
(P = 0.026) increase in treatment effect as assessed by gross 
tumor inspection on experiment day nine (Figures 4 and 5). 
Control groups demonstrated no effect from irradiation, and 
tumors in the MDT-NP treated/no ablation group were unal-
tered by the presence of MDT-NPs (Figure 5). Histologically, 
a congruent pattern was observed: no evidence of thermal 
injury or other tissue damage was noted in control mice (Fig-
ure 6A), whereas mice treated with MDT-NPs and exposed 
to four fractionated photothermal ablations demonstrated 
significant thermal injury with coagulative tumor necrosis, 
hemorrhage, and edema (Figure 6B).
Discussion
For fractionated photothermal therapy to be possible, 
  photothermal NPs must maintain their intratumoral location 
  following photothermal activation. To the authors’ knowledge, 
the intratumoral fate of photothermal NPs following one or 
more photothermal treatments has not been previously well 
characterized. MDT-NPs are a novel tool which has allowed 
the intratumoral fate of photothermal NPs following pho-
toablation to be studied. Multimodal MDT-NPs can easily 
be both tracked using fluorescence imaging and repeatedly 
excited for photoablation with a NIR laser.
In the reported experiments, MDT-NPs were clearly able 
to be imaged within the tumors following one or more pho-
tothermal treatments. The presence of MDT-NPs within the 
tumor following photothermal treatments (as demonstrated 
by NIR imaging) and their ability to be repeatedly heated in 
vitro (Figure 1C) suggests that they may be used for additional 
photothermal treatments (fractionated photothermal therapy). 
The ability to image MDT-NPs within the tumor over time 
can be used to guide fractionated photothermal therapy.
It was observed that MDT-NPs remain in the intratumoral 
position for days following photothermal treatment in the 
4T1 murine mammary carcinoma model. It is possible that the 
kinetics of nanomaterial extravasation are different for other 
tumor types with different lymphatic and vascular patterns. 
This would be a subject worthy of further investigation.
Intratumoral persistence and function of MDT-NPs 
following photoablation may allow the use of lower laser 
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intensities to treat tumors compared to single ablation 
strategies. It is noteworthy that in the present study, very 
low laser intensity (625 mW/cm2) was required to achieve 
fractionated photothermal ablation compared to previ-
ous reports of photothermal ablation (4 W/cm2).1,10 The 
minimal number of ablations needed to achieve complete 
tumor destruction is not investigated in the present study 
and very likely depends on many factors, such as tumor 
type, tumor size, tumor location, nanoparticle construct 
(eg, NIR-absorbing component used for ablation), intratu-
moral distribution of NPs, and concentration of MDT-NPs 
within tumors.17 Such investigations would represent the 
next step in advancing the concept of fractionated tumor 
photothermal ablation toward clinical application. The 
theoretical advantages of fractionated photothermal therapy 
are evident. Foremost, if complete tumor destruction is 
not obtained on the initial photothermal treatment, then 
subsequent successive treatments can be performed using 
the fractionated approach. Absolute dosing of nanomateri-
als for photothermal therapy may be minimized with the 
fractionated treatment paradigm.
Conclusion
MDT-NPs are unique nanomaterials that maintain 
their   fluorescent and photothermal properties after 
  photoactivation. In the 4T1 murine breast cancer model, 
MDT-NPs remain within the tumor following photother-
mal treatments. It has been demonstrated MDT-NPs can 
  therefore be utilized as mediators of fractionated photo-
thermal therapy. Fractionated treatments can be guided 
by the ability to image MDT-NPs within the tumor using 
fluorescence imaging techniques.
The concept of image-guided, fractionated photothermal 
ablation is one which has the potential to expand the effi-
cacy of photothermal therapy for clinical application while 
minimizing the morbidity of cancer care. This new paradigm 
should allow photothermal treatments to be delivered and 
modulated depending on tumor response to achieve the 
desired clinical effect.
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Figure 5 Digital photographs of tumors from representative mice from each group 
taken at 9 days of (A) multidye theranostic nanoparticle/no ablation, (B) multidye 
theranostic  nanoparticle/one  ablation,  (C)  control/one  ablation,  (D)  multidye 
theranostic  nanoparticle/four  ablations,  and  (E)  control/four  ablations.  There  is 
significantly greater tumor destruction seen in the sequentially ablated tumor (D) 
compared to mice receiving one ablation (B) or control mice (A, C, and E).
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Figure 6 (A) Hematoxylin and eosin stained tumor section of a representative 
control/four ablations mouse, 4×. There is no evidence of thermal injury or other 
tissue damage; a viable tumor nodule is clearly demarcated with a healthy skin 
surface. (B) Hematoxylin and eosin stained tumor section of multidye theranostic 
nanoparticle/four ablations, 2×. Thermal injury is evident with coagulative tumor 
necrosis, hemorrhage, and edema in the treated tissues.
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